Boston Scientific Corporation (NYSE:BSX) Shares Acquired by Larson Financial Group LLC

Larson Financial Group LLC increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.1% during the first quarter, Holdings Channel reports. The fund owned 54,556 shares of the medical equipment provider’s stock after acquiring an additional 2,147 shares during the quarter. Larson Financial Group LLC’s holdings in Boston Scientific were worth $5,504,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BSX. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after acquiring an additional 21,173 shares during the period. Highview Capital Management LLC DE raised its holdings in shares of Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after acquiring an additional 1,439 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of Boston Scientific by 40.2% during the fourth quarter. Proficio Capital Partners LLC now owns 5,333 shares of the medical equipment provider’s stock valued at $476,000 after acquiring an additional 1,528 shares during the period. Finally, Commonwealth Equity Services LLC lifted its position in Boston Scientific by 7.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 227,915 shares of the medical equipment provider’s stock worth $20,357,000 after buying an additional 16,054 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the firm’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president directly owned 22,235 shares of the company’s stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares of the company’s stock, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 461,970 shares of company stock worth $47,755,193 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of research analyst reports. Leerink Partners initiated coverage on shares of Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price for the company. BTIG Research reiterated a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Citigroup restated a “buy” rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Twenty-two investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $116.09.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $104.39 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The firm has a fifty day moving average price of $103.43 and a two-hundred day moving average price of $100.76. The company has a market cap of $154.43 billion, a PE ratio of 76.19, a price-to-earnings-growth ratio of 2.68 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the firm earned $0.56 EPS. The business’s revenue was up 20.9% on a year-over-year basis. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.